Skip to main content

Structure guided inhibition of IDOL to treat atherosclerosis and the metabolic syndrome

Project description

Treating the world’s expanding waistlines

Sedentary lifestyles, increased screen time, overnutrition and obesity are all characteristics of metabolic syndrome (MetS), which is increasing to epidemic proportions. MetS is associated with an increase in cardiovascular disease risk and type 2 diabetes mellitus. Treatment options for MetS-associated comorbidities, including dyslipidaemia, diabetes, obesity, and fatty-liver disease, are far from optimal. The EU-funded CHANCE project will address this challenge by capitalising on the high-resolution 3D structure of IDOL (inducible degrader of the low-density lipoprotein receptor), which can modulate cholesterol levels. The project will identify and validate small-molecule IDOL inhibitors by using a structure-guided development pipeline that combines an established virtual ligand docking protocol, and in vitro and in vivo validation.

Host institution

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
No data